| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC3367 |
| Trial ID | NCT05767359 |
| Disease | Smoldering Myeloma | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Carvykti|Ciltacabtagene Autoleucel|Cilta-cel|JNJ-68284528 |
| Location approved | US, EU, UK, Japan, Australia, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | CAR- PRISM (PRecision Intervention Smoldering Myeloma) |
| Year | 2023 |
| Country | United States |
| Company sponsor | Dana-Farber Cancer Institute |
| Other ID(s) | 22-546 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||